New research indicates that different formulations of GLP-1 receptor agonists may offer diverse benefits including blood sugar, blood pressure, and cholesterol improvements, paving the way for tailored treatments beyond obesity management.
A new analysis suggests GLP-1 medicines may do more than help people lose weight, with some drugs and doses appearing to affect blood sugar, blood pressure and cholesterol differently. Researchers from the University of Pennsylvania, Yale School of Medicine and UT Southwestern Medical Center reviewed 19 randomised controlled trials involving 13,117 adults with overweight or obesity and compared oral and injectable GLP-1 receptor agonists across several cardiometabolic measures.
The team found that higher-dose regimens tended to deliver the broadest improvements overall. Semaglutide 7.2 mg ranked highest in its combined score, followed by orforglipron 36 mg and semaglutide 2.4 mg. All three achieved average placebo-adjusted weight loss of at least 10%, but the study suggested that each had different strengths beyond the scales. Semaglutide was stronger on weight, waist circumference and LDL cholesterol, while orforglipron appeared to perform better on blood sugar, HDL cholesterol and systolic blood pressure.
The findings add to broader evidence that GLP-1 medicines can influence cardiovascular and metabolic health in ways that go beyond appetite suppression. Clinical summaries from Drugs.com and GoodRx note that these medicines can lower systolic blood pressure, often by about 3 to 5 points, though they are not approved specifically to treat hypertension. Separately, published research has pointed to GLP-1 drugs having effects independent of weight loss, with biological actions in the pancreas, liver, stomach, brain and kidneys helping explain why their benefits may extend beyond obesity treatment alone.
The researchers said the goal is not to crown one winner for every patient, but to support more tailored prescribing. In the study’s news release, senior author Yong Chen said clinicians should take a more comprehensive and individual approach, while co-author Yuan Lu said blood pressure, cholesterol and glucose control should all be considered alongside weight loss when matching a treatment to a patient’s goals. The authors also noted that their composite score compares relative performance across risk factors and does not prove differences in hard cardiovascular outcomes.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
